Literature DB >> 31420628

[Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].

H L Zhu1, Q DU1, W L Chen1, X X Zuo1, Q Z Li1, S J Liu1.   

Abstract

OBJECTIVE: To analyze the expression profile of serum cytokines in patients with systemic sclerosis (SSc) and explore its possible regulatory mechanisms.
METHODS: Serum and DNA of peripheral blood mononuclear cells were collected from 30 SSc patients and 80 normal controls (NCs). According to the presence or absence of interstitial lung disease (ILD) in SSc, the patients were divided into SSc with ILD group and SSc without ILD group. According to the degree of skin involvement, the patients were divided into diffuse systemic scleroderma (dcSSc) group and limited systemic scleroderma (lcSSc) group. According to the presence of anti-topoisomerase-1 antibody (anti-Scl-70 antibody) in the serum of patients with SSc, they were divided into SSc Scl-70 (+) group and SSc Scl-70 (-) group. 27 cytokines in serum were detected by Luminex MAGPIX detection system and Bio-Plex Pro Human Cytokine 27-plex Assay kit: interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12P70, IL-13, IL-15, IL-17, basic fiber growth factor (BASIC FGF), eotaxin, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-γ (IFN-γ), interferon-gamma induced protein 10(IP-10), monocyte chemotactic protein 1(MCP-1), macrophage inflammatory protein-1α (MIP-1α), macrophage inflammatory protein 1β(MIP-1β), platelet-derived growth factor BB (PDGF-BB), regulated on activation in normal T-cell expressed and secreted (RANTES), tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor(VEGF). Methylation sites were detected by Illumina 450K methylation chip.
RESULTS: Compared with NCs group, the expression of 12 cytokines (BASIC FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-6, IP-10, MCP-1, TNF-α and RANTES) in the SSc group significantly increased (P<0.05), IL-5 was decreased expression in the SSc group (P<0.05), there was no significant difference in the expressions of the other 14 cytokines. Compared with lcSSc group, 9 cytokines (eotaxin, IL-5, MCP-1, IL-2, RANTES, IL17A, IL-8, MIP-1β and PDGF-BB) increased in dcSSc group, but there was no significant difference. Compared with SSc without ILD group, IL-15 increased in SSC with ILD group [18.2 (172.97) ng/L vs. 2.03(0.05) ng/L, P<0.05]. Compared with SSc Scl-70 (-) group, the expression of IP-10 decreased in SSc Scl-70 (+) group [1 030 (2 196.6) ng/L vs. 1 878 (2 964) ng/L, P<0.05]. The correlation analysis of serum cytokines with erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) showed that IL-6 was positively correlated with ESR (r =0.04, P= 0.017), MCP-1 (r=0.49, P=0.043) and MIP-1β (r=0.41, P=0.007) positively correlated with CRP. By analyzing the changes of methylation sites of cytokines, it was found that cg17744604 in IL-10 TSS1500 region, cg06111286 in IL-12P70 TSS200 region, cg07935264 in IL-1β TSS200 region, cg01467417 in IL-1ra TSS1500 region, cg03989987 in IL-1ra 5'UTR region and cg21099624 in VEGF TSS200 region were all hypomethylated.
CONCLUSION: There were different cytokines expression profiles in the serum of SSc patients, and the altered cytokines were correlected with the degree of skin damage and pulmonary fibrosis. Many cytokines were regulated by methylation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31420628      PMCID: PMC7433485          DOI: 10.19723/j.issn.1671-167X.2019.04.021

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  17 in total

Review 1.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Authors:  Minoru Hasegawa; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

4.  Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.

Authors:  M Hasegawa; M Fujimoto; K Kikuchi; K Takehara
Journal:  J Rheumatol       Date:  1997-02       Impact factor: 4.666

Review 5.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

6.  Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody.

Authors:  Toshinori Takada; Kazumasa Ohashi; Masachika Hayashi; Katsuaki Asakawa; Takuro Sakagami; Toshiaki Kikuchi; Shinji Sato
Journal:  Respir Med       Date:  2018-06-15       Impact factor: 3.415

Review 7.  Systemic sclerosis.

Authors:  Christopher P Denton; Dinesh Khanna
Journal:  Lancet       Date:  2017-04-13       Impact factor: 79.321

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 9.  Cytokines in rheumatoid arthritis - shaping the immunological landscape.

Authors:  Iain B McInnes; Christopher D Buckley; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

10.  Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

Authors:  Désirée van der Heijde; James Cheng-Chung Wei; Maxime Dougados; Philip Mease; Atul Deodhar; Walter P Maksymowych; Filip Van den Bosch; Joachim Sieper; Tetsuya Tomita; Robert Landewé; Fangyi Zhao; Eswar Krishnan; David H Adams; Beth Pangallo; Hilde Carlier
Journal:  Lancet       Date:  2018-10-22       Impact factor: 79.321

View more
  3 in total

1.  Genetic Association between TNFA Polymorphisms (rs1799964 and rs361525) and Susceptibility to Cancer in Systemic Sclerosis.

Authors:  Joanna Kosałka-Węgiel; Sabina Lichołai; Sylwia Dziedzina; Mamert Milewski; Piotr Kuszmiersz; Anna Rams; Jolanta Gąsior; Aleksandra Matyja-Bednarczyk; Helena Kwiatkowska; Mariusz Korkosz; Andżelika Siwiec; Paweł Koźlik; Agnieszka Padjas; Wojciech Sydor; Jerzy Dropiński; Marek Sanak; Jacek Musiał; Stanisława Bazan-Socha
Journal:  Life (Basel)       Date:  2022-05-07

2.  Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients.

Authors:  A Ottria; A T Hoekstra; M Zimmermann; M van der Kroef; N Vazirpanah; M Cossu; E Chouri; M Rossato; L Beretta; R G Tieland; C G K Wichers; E Stigter; C Gulersonmez; F Bonte-Mineur; C R Berkers; T R D J Radstake; W Marut
Journal:  Front Immunol       Date:  2020-05-22       Impact factor: 7.561

Review 3.  Epigenetic Modifications in the Pathogenesis of Systemic Sclerosis.

Authors:  Jiangfan Yu; Rui Tang; Ke Ding
Journal:  Int J Gen Med       Date:  2022-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.